David M. Ross

D Bedford Park
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 146 publications

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Journal: HemaSphere
Published: April 27, 2026

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere
Published: March 18, 2026

Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CML.

Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CML.

Journal: Leukemia & lymphoma
Published: January 05, 2026

Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Journal: Blood advances
Published: October 27, 2025

Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Journal: Blood advances
Published: October 27, 2025

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Journal: HemaSphere
Published: October 23, 2025

Clinical and biological predictors of treatment-free remission in CML.

Clinical and biological predictors of treatment-free remission in CML.

Journal: Leukemia & lymphoma
Published: October 10, 2025

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology
Published: September 14, 2025

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Journal: Blood
Published: August 26, 2025

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Journal: Blood advances
Published: August 19, 2025

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Journal: Blood advances
Published: August 19, 2025

Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Journal: Cancers
Published: August 14, 2025
Showing 1-12 of 146

Last Updated: 09/26/2026